In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9

Biochemical and Biophysical Research Communications

Volumn 450, Issue 4, 2014, Pages 1422-1426

  Zhen, Shuai ^a,b,c,d   Hua, Ling ^c   Takahashi, Y ^d   Narita, S ^d   Liu, Yun Hui ^c   Li, Yan ^e  

^a Department of Andrology   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^d KYOTO UNIVERSITY   (Japan)

^e Baoji Hospital of Traditional Chinese Medicine   (China)

Author keywords

BALB C nude mouse; CRISPR Cas9; E6; E7; HPV16; Keyword; Tumor formation

Indexed keywords

BALB/C NUDE MOUSE; CRISPR/CAS9; E6; E7; HPV16; TUMOR FORMATION;

ALPHAPAPILLOMAVIRUS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DNA PRIMERS; FEMALE; HUMANS; UTERINE CERVICAL NEOPLASMS;

EID: 84906083667     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.07.014     Document Type: Article

References (38)

1. J. Doorbar Molecular biology of human papillomavirus infection and cervical cancer Clin. Sci. 110 2006 525 541
2. S. Goldie A public health approach to cervical cancer control: considerations of screening and vaccination strategies Int. J. Gynecol. Obstet. 94 2006 95 105
3. Shuai Zhen, Chen-Ming Hu, and Li-Hong Bian Glutathione S-transferase polymorphism interactions with smoking status and HPV infection in cervical cancer risk: an evidence-based meta-Analysis PLOS ONE 8 12 2013 e83497 doi: 10.1371
4. K. Munger, A. Baldwin, K. Edwards, H. Hayakawa, C. Nguyen, and M. Owens Mechanisms of human papillomavirus induced oncogenesis J. Virol. 78 2004 11451 11460
5. E.M. de Williers Heterogeneity of the human papillomavirus group J. Virol. 63 1989 4898 4903
6. F.X. Bosch, M.M. Manos, N. Muñoz, M. Sherman, A.M. Jansen, and J. Peto et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group J. Natl. Cancer Inst. 87 1995 796 802
7. H. zur Hausen Papillomaviruses and cancer: from basic studies to clinical application Nat. Rev. Cancer 2 2002 342 350
8. A. Nishimura, T. Nakahara, T. Ueno, K. Sasaki, S. Yoshida, and S. Kyo et al. Requirement of E7 oncoprotein for viability of HeLa cells Microbes Infect. 8 2006 984 993
9. B.A. Werness, A.J. Levine, and P.M. Howley Association of human papillomavirus types 16 and 18 E6 proteins with p53 Science 248 1990 76 79
10. M. Scheffner, J.M. Huibregtse, R.D. Vierstra, and P.M. Howley The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 Cell 75 1993 495 505
11. K. Munger, B.A. Werness, N. Dyson, W.C. Phelps, E. Harlow, and P.M. Howley Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product EMBO J. 8 1989 4099 4105
12. N. Dyson, P.M. Howley, K. Munger, and E. Harlow The human papilloma virus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product Science 343 1989 934 937
13. N. Dyson, P. Guida, K. Munger, and E. Harlow Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins J. Virol. 66 1992 6893 6902
14. R. Davies, R. Hicks, T. Crook, J. Morris, and K. Vousden Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation J. Virol. 67 1993 2521 2528
15. J.O. Funk, S. Waga, J.B. Harry, E. Espling, B. Stillman, and D.A. Galloway Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein Genes Dev. 11 1997 2090 2100
16. D.L. Jones, R.M. Alani, and K. Munger The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21-mediated inhibition of cdk2 Genes Dev. 11 1997 2101 2111
17. K. Zerfass-Thome, W. Zwerschke, B. Mannhardt, R. Tindle, J.W. Botz, and P. JansenDurr Inactivation of the cdk inhibitor p27 by the human papillomavirus type 16 E7 oncoprotein Oncogene 13 1996 2323 2330
18. R.M. Alani, and K. Munger Human papillomaviruses and associated malignancies J. Clin. Oncol. 16 1998 330 337
19. P. Horvath, and R. Barrangou CRISPR/Cas, the immune system of bacteria and archaea Science 327 2010 167 170
20. H. Deveau, J.E. Garneau, and S. Moineau CRISPR/Cas system and its role in phage-bacteria interactions Annu. Rev. Microbiol. 64 2010 475 493
21. S.W. Cho, S. Kim, J.M. Kim, and J.S. Kim Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease Nat. Biotechnol. 31 2013 230 232
22. P. Mali, I. Yang, K.M. Esvelt, J. Aach, and M. Guell RNA-guided human genome engineering via Cas9 Science 339 2013 823 826
23. M. Jinek, A. East, A. Cheng, S. Lin, and E. Ma RNA-programmed genome engineering in human cells Elife 2 2013 e00471
24. Hirotaka Ebina, Naoko Misawa, Yuka Kanemura, and Yoshio Koyanagi Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus Sci. Rep. 3 2013 2510
25. Wataru Fujii, Kurenai Kawasaki, Koji Sugiura, and Kunihiko Naito Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease Nucleic Acids Res. 41 20 2013 e187 10.1093/nar/gkt772
26. P. Mali et al. RNA-guided human genome engineering via Cas9 Science 339 2013 823 826
27. C. Cain, and S. Writer CRISPR Genome Editing 2013 SciBX pp. 1-3
28. E. Schwarz et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells Nature 314 1985 111 114
29. J.T.C. Chang, S.H. Chan, C.Y. Lin, T.Y. Lin, H.M. Wang, and C.T. Liao et al. Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15 Mol. Cancer Ther. 6 2007 2271 2279
30. N. Sunaga, K. Miyajima, M. Suzuki, M. Sato, M.A. White, R.D. Ramirez, J.W. Shay, A.F. Gazdar, and J.D. Minna Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer Cancer Res. 64 2004 4277 4285
31. Mitsuo Yoshinouchi, Taketo Yamada, Masahiro Kizaki, Jin Fen, Takeyoshi Koseki, Yasuo Ikeda, Tatsuji Nishihara, and Kenji Yamato In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA Mol. Ther. 8 5 2003 762 768
32. M.A. Quinn, J.L. Benedet, F. Odicino, P. Maisonneuve, U. Beller, W.T. Creasman, A.P. Heintz, H.Y. Ngan, and S. Pecorelli Carcinoma of the cervix uteri. FIGO 26th Annual Report on the results of treatment in Gynecological cancer Gynaecol. Obstet. 95 2006 S43 S103
33. Ryan M. Walsh, and Konrad Hochedlinger A variant CRISPR-Cas9 system adds versatility to genome engineering PNAS 39 2013 110
34. A. Klug The discovery of zinc and their applications in gene regulation and genome manipulation Annu. Rev. Biochem. 79 2010 213 231
35. H. Wang, H. Yang, C.S. Shivalila, M.M. Dawlaty, A.W. Cheng, F. Zhang, and R. Jaenisch One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering Cell 153 4 2013 910 918
36. W. Gu, L. Putral, K. Hengst, N.A. Sauders, G. Leggatt, and N.A. McMillan Inhibition of cervical cancer growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes Cancer Gene Ther. 13 2006 2006 1023 1032
37. J.T. Chang, T.F. Kuo, Y.J. Chen, C.C. Chiu, Y.C. Lu, H.F. Li, C.R. Shen, and A.J. Cheng Highly potent and specific siRNAs against E6 or E7 genes of HPV 16- or HPV18-infected cervical cancers Cancer Gene Ther. 17 2010 2010 827 836
38. W.L. Liu, N. Green, L.W. Seymour, and M. Stevenson Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma Cancer Gene Ther. 16 2009 764 775